Bristol Myers Squibb stock holds as earnings and guidance stay in view

Bristol Myers Squibb (US0897961004) is framed today by its 2025 numbers: revenue of $48.3 billion, diluted EPS of $6.73, and a reported full year free cash flow of $12.0 billion. The companys investor relations page remains the official starting point for shareholders tracking the latest filings and updates.

Revenue and EPS set the base

The 2025 revenue figure of $48.3 billion gives the stock a current earnings backdrop, while diluted EPS of $6.73 and free cash flow of $12.0 billion show how management ended the year. Those figures matter because they define the level that any 2026 update will be measured against, even before a fresh market reaction is visible.

For comparison, the companys reported 2025 revenue and earnings remain the latest periodized reference point in the public record. The combination of $48.3 billion in sales and $6.73 in EPS offers a concrete baseline for the next quarter, and the $12.0 billion free cash flow number adds balance-sheet relevance.

Guidance and capital returns

Bristol Myers Squibb also used its 2025 results to frame capital allocation through cash generation and shareholder returns. The $12.0 billion free cash flow figure supports that picture, and the company has continued to present its investor materials through Bristol Myers Squibb investor relations.

That matters for the stock because the market typically reacts first to the next reported shift in revenue, EPS, and cash generation rather than to the business description itself. In 2025, the gap between $48.3 billion in sales and $6.73 in diluted EPS is the clearest operating summary available in the companys latest public figures.

Opdivo and Opdualag

The companys product mix remains centered on oncology and immunology, with products such as Opdivo and Opdualag among the best-known brands in the portfolio. Those medicines matter because Bristol Myers Squibb has historically tied its revenue mix to key specialty therapies rather than to a single consumer-facing product line.

The product slate is relevant to investors mainly because it supports the reported 2025 revenue base of $48.3 billion. When a company of this size reports $6.73 in diluted EPS and $12.0 billion in free cash flow in the same year, the market usually weighs product durability and pipeline execution together.

Stock context today

Bristol Myers Squibb stock is therefore best read through its latest 2025 financial base, not through a headline price move. The key numbers are still $48.3 billion in revenue, $6.73 in diluted EPS, and $12.0 billion in free cash flow, all tied to the companys 2025 reporting cycle.

That leaves the next earnings update as the main catalyst for any new rerating, with the companys own investor relations materials the primary source for future disclosures. Until then, the latest reported figures define the frame for the share price and the market story.